Long-term survivorship rates among previously treated advanced melanoma patients achieving objective response (OR) with lifileucel.
Peter Mohr, Jiayi Zhou, M. Kurt, Aaryan Vashisht et autres
9592 Background: Durability of response and associated long-term survival benefits of modern cancer therapies are often manifested as plateaus in duration of response (DoR) and overall survival (OS) curves for responders. In the single-arm, Phase 2 C-144-01 trial, unresectable/metastatic melanoma patients who …
de, us, gb (code pays fourni par la source)